SNORA23: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA23

NCBI ID: G677808

SNORA23

Other Name(s): small nucleolar RNA, H/ACA box 23 | ACA23 | Small nucleolar RNA, H/ACA box 23

SNORA23: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a crucial role in various cellular processes, including DNA replication, gene expression, and RNA splicing. H/ACA box 23 (H/ACA-23) is a specific snRNA that has been identified as a potential drug target or biomarker. This article will conduct an in-depth study of SNORA23 and explore its pharmacological value and clinical application prospects.

Biological functions of SNORA23

SNORA23 is a 23nt snRNA that has multiple biological functions in cells. SNORA23 was originally discovered in the human genome database and is expressed in multiple species. Studies have shown that SNORA23 regulates DNA replication and cell cycle progression during the cell cycle. In mitosis, SNORA23 binds to tubulin on spindle microtubules and plays an important role in spindle assembly and separation. In addition, SNORA23 is also involved in regulating cell cycle progression and apoptosis.

Pharmacological value of SNORA23

As a new drug target, SNORA23 has broad application prospects in the field of drug research and development. Currently, multiple research teams are exploring SNORA23 as a potential drug to treat cancer and other diseases. For example, some research teams have found that SNORA23 can inhibit the growth and spread of tumor cells by inhibiting its expression, thus having potential anti-cancer effects. In addition, some research teams have also found that SNORA23 can be used as a biomarker for the treatment of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.

Clinical application prospects of SNORA23

As a new drug target, SNORA23 has broad application prospects in the fields of drug development and clinical application. With in-depth research on the biological functions of SNORA23, the mechanism of action of SNORA23 can be better understood and its potential as a drug target can be explored. In addition, SNORA23, as a new biomarker, can be used to predict disease risk and disease progression. These findings lay a solid foundation for the clinical application of SNORA23 and provide new ideas for the treatment of related diseases.

in conclusion

SNORA23 is a snRNA with multiple biological functions and has broad application prospects in drug development and clinical applications. With in-depth research on the biological functions of SNORA23, the mechanism of action of SNORA23 can be better understood and its potential as a drug target can be explored. In addition, SNORA23, as a new biomarker, can be used to predict disease risk and disease progression. In summary, SNORA23 is a drug target with great potential and deserves further study.

Protein Name: Small Nucleolar RNA, H/ACA Box 23

The "SNORA23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets